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Background/purpose: Despite high long-term survival rates in patients with Wilms tumor, there is a need to
develop better prognostic biomarkers in order to maximize cure while avoiding treatment-associated morbidities.
Tumor-associated macrophages have been recently associated with poorer prognosis and increased disease
progression in a number of adult cancers. We investigated the relationship between macrophages and
clinicopathological fators in this pediatric solid tumor.
Methods: Tissue microarray sections of 124 Wilms tumor cases obtained from the Cooperative Human Tissue
Network were stained with CD68, a macrophage marker using standard immunohistochemical techniques and
quantified using digital image processing techniques. Macrophage densities were correlated by tumor stage, and
survival analyses were conducted with available clinical data. Immunohistochemistry was performed on 25
additional Wilms tumor cases obtained from the tumor bank at Columbia University Medical Center and correlated
with presence of tumor microvascular invasion.
Results: Mean macrophage count densities in stage IV tumors were significantly greater than densities in stage I
and III tumors (p=.021, .036). Although the overall and disease-free survival did not differ between high and low
macrophage presence groups across all stages, increased macrophage presence was associated with decreased
disease-free survival in patients with stage II tumors (p=0.035). Increased macrophage presence may have also
correlated with decreased disease-free survival in stage IV patients, but the sample size was too small to allow
detection of this difference with significance (p=0.575). Increased macrophage presence was associated with tumor
microvascular invasion (p=0.0004).
Conclusion: Our results suggest that macrophage recruitment may be associated with disease progression in
Wilms tumor. Quantitation of macrophage presence may therefore be a useful adjunct in refining staging
algorithms for patients with stage II Wilms tumor. Such data might be useful in the effort to reduce the risk of
adverse effects associated with under- or overtreatment of this neoplasm.
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Wilms Tumor is the most common pediatric renal ma-
lignancy, and the second most common abdominal solid
tumor in children [1]. There are approximately 500 new
cases diagnosed in the United States each year. Due to
the development of evidence-based treatment protocols
and their refinement by the multidisciplinary cooperative
groups over the last 40 years, long-term survival rates in* Correspondence: jjk47@columbia.edu
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reproduction in any medium, provided the orWilms tumor have dramatically improved [2]. With these
advances, a focus on refining therapy to reduce adverse ef-
fects while maintaining excellent outcomes has become
increasingly important. However, an array of biomarkers
that may be useful in this refinement are still lacking.
Thus, new biomarker discovery could reduce both
overtreatment of low-risk tumors and undertreatment of
high-risk tumors, limiting unnecessary morbidity and un-
desired outcomes in these children.
Treatment of Wilms tumor in North America is cur-
rently based upon tumor staging, the presence of favorable
or unfavorable histology, and age, using protocols. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Traditionally, tumor stage has correlated closely with
disease-free and overall survival [5]. Accurate tumor sta-
ging is therefore critical to determining appropriate treat-
ment. Stage I and II tumors are amenable to surgical
resection with or without limited chemotherapy, while
Stage III and IV tumors require more intensive treatment,
including extended adjuvant chemotherapy regimens and
in some cases, radiation therapy.
The diagnosis of stage II Wilms tumor offers a par-
ticular prognostic challenge, as these children may be at
higher risk of understaging. Some authors have sug-
gested that this depends on the number of lymph nodes
sampled. In a large retrospective study, Kieran et al.
found that the likelihood of finding a positive lymph
node, and thus upstaging to stage III, was greater when
more than 7 were sampled, suggesting that insufficient
sampling may limit the accuracy of stage determination
[6]. Understaging could therefore lead to inadequate treat-
ment of Stage III tumors, with consequent poorer out-
comes [7,8]. Stage II patients in whom lymph nodes were
not sampled experienced an increase in local tumor recur-
rence, again associated with poorer outcomes [9]. Conse-
quently, there is a clear need to identify better prognostic
predictors in patients with Stage II tumors.
Recently, tumor-associated macrophages (TAMs) have
become the focus of significant interest for their ability
to predict tumor prognosis in a number of malignancies
[10]. As cellular effectors of the innate immune system,
macrophages play essential roles in a myriad of pro-
cesses, including immune response, inflammation, tissue
remodeling, and injury repair [11]. Macrophages are also
major constituents of tumor stroma, and an emerging
body of evidence suggests that they play a prominent
role in tumor growth and survival. In particular,
M2 (alternatively activated) macrophages secrete anti-
inflammatory cytokines, promote tissue repair/remodel-
ing, angiogenesis, and elicit downregulation of T-cells
and other immune effectors [12,13]. Similarly, a number
of experimental studies have demonstrated the ability of
neoplastic cells to recruit M2 macrophages, which sup-
ports tumor growth, stimulates tumor angiogenesis, sup-
presses host immunity, and promotes invasion and
metastasis [14,15]. Thus, TAMs have attracted signifi-
cant interest both as biomarkers and as potential targets
for novel therapies [13].
A number of clinical studies have previously linked
macrophage presence and prognosis in a variety of adult
human cancers, including breast, endometrial, renal cell
carcinoma, poorly differentiated thyroid cancer, and
Hodgkin’s lymphoma [16-20]. In most prior reports,
high numbers of macrophages have been correlated with
worse prognosis, more rapid tumor progression, and
decreased disease-specific survival [10]. Consistent withthese observations, tumor progression and metastasis
are significantly reduced in macrophage-deficient experi-
mental models [21]. Taken together, these data suggest
that macrophage presence might also be useful as a bio-
marker in pediatric solid tumors. In this study, we sought
to examine the relationship between macrophage presence
and clinicopathological factors in Wilms tumor.
Methods
Immunohistochemistry
Tissue microarrays (TMAs) containing 154 unique Wilms
tumor cases were obtained from the Cooperative Human
Tissue Network tissue bank (CHTN, Columbus, OH), by
application to the Renal Tumors Biology Subcommittee of
the Children’s Oncology Group (COG). Each case includes
two to four 1-millimeter cores of paraffin embedded tissue
mounted onto the TMA in random order. 27 cases were
removed from analysis due to incomplete clinical informa-
tion. An additional 3 cases containing stage V disease were
eliminated, leaving 124 for final analysis.
TMAs were stained for CD68 using standard immuno-
histochemistry protocols. Slides were warmed at 40°C
overnight and deparaffinized in xylene, followed by rehy-
dration in decreasing concentrations of ethanol. Antigen
retrieval was carried out with target retrieval solution
pH9 (DAKO, Carpinteria, CA) for 15min in a steamer at
100°C, then allowed to cool to room temperature for
20min. The slides were blocked for 30min at room
temperature with CAS blocking reagent (Invitrogen,
Carlsbad, CA) to reduce non-specific staining. Mouse
anti-human CD68 monoclonal antibodies (clone PG-M1,
DAKO), diluted 1:200 in CAS block were incubated with
the slides overnight at 4°C. After thorough rinsing with
phosphate-buffered saline, biotinylated anti-mouse sec-
ondary antibodies were incubated with slides at room
temperature for 30min. Development of the stain was
performed using 3,3’-Diaminobenzidine (DAB) chromo-
gen (Vector Laboratories, Burlingame, CA) according to
manufacturer specifications. Tonsillar tissue was used as
positive control.
Macrophage counting
High-resolution digital images were taken of each tissue
core at 4× magnification using a digital microscope
camera (Diagnostic Instruments, Sterling Heights, MI)
mounted on a Nikon E600 microscope. Images were
then loaded into Photoshop CS3 (Adobe Systems, San
Jose, CA) with scientific image processing software
(Reindeer Graphics, Asheville, NC). Although the size of
tissue cores was estimated to be 1mm in diameter, we
accurately measured the size of each core in pixels using
the magnetic lasso feature to accommodate minor
variation. The image threshold was then set to eliminate
the core background and isolate the immunostained
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and eliminate non-specific background noise, the Binary
Image Morphology function was set to Open, with a coef-
ficient of 4 and depth of 2. Background noise was fur-
ther reduced by eliminating individual spots containing
less than 6 pixels (Figure 1). Discrete macrophages were
counted using the Count feature. A count density per in-
dividual case was then calculated using the following
formula:
Count Density ¼ Average Macrophage Number
Average Core Area Pixelsð Þ  Constant
The average macrophage number was calculated as
the mean number of macrophages in all tissue cores per
individual case. An arbitrary constant was used to facili-
tate ease of analysis and scoring.
Statistical analysis
ANOVA and respective post-hoc T-tests using the Tukey
criteria were performed on the count densities of all
Wilms tumor cases, stratified by overall tumor stage. To
determine associations between count density and dis-
ease free and overall survival, analyses were performed
using the Logrank test. We chose a count density lessFigure 1 High and Low Macrophage Count Density Wilms Tumor Tiss
density Wilms’ Tumor tissue core, before and after image processing. (B) Rethan 10 to represent a low macrophage presence, and a
count density greater than 10 to represent high macro-
phage presence. Separate categorical analysis using Fish-
er’s exact test was used to corroborate significant
associations found between count density and survival.Macrophage presence and microvascular invasion
Due to the lack of pathologic data for tissues obtained
from the CHTN, we were unable to assess the presence of
microvascular invasion in the TMA cases. Therefore, we
acquired 25 separate Wilms tumor cases from the
Columbia University Medical Center tumor bank, with ac-
companying de-identified pathology reports. Because the
samples contained much more tissue than the cores avail-
able on a tissue microarray, the macrophage counting
method was adjusted. Images were taken of ten macro-
phage hot-spots (areas within the tissue containing the
highest density of macrophages) per Wilms tumor case, at
20x magnification. The images were then loaded into
Photoshop CS3 and macrophages were counted using the
same methods described above. The average counts of
three images containing the greatest number of macro-
phages per Wilms tumor case were recorded and correlated
against presence of microvascular invasion. Count densitiesue Cores. (A) Representative example of a low macrophage count
presentative example of a high macrophage count tissue core.
Figure 2 Comparison of Mean Macrophage Count Densities by
Tumor Staging. ANOVA demonstrated a significant difference in
mean macrophage count densities when stratified by tumor stage.
Post-hoc T-test analysis using Tukey’s method showed a significant
difference in mean macrophage count density between stage IV
and stage I, and stage IV and stage III tumors.
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Statistical analysis was performed using Fisher’s exact test.
Results
Patient characteristics
A total of 154 unique Wilms tumor cases with accom-
panying tissue cores were provided by the Children’s
Oncology Group. 124 cases were selected for final ana-
lysis, as 30 were either missing corresponding clinical
information or were stage V tumors. 47 patients had
overall stage I tumors, 20 were stage II, 45 were stage
III, and 12 were stage IV. Two patients had received
chemotherapy prior to surgery: one was designated as
stage III, the other as stage IV. The mean age at time of
surgery was 39.7 months (Range 2–120, Stdev 29.5). 53%
of patients were female and 47% were male. 60% patients
were Caucasian, 25% were African American, 13% were
Hispanic, and 2% Other. The overall cumulative long-
term survival rate was 87.4% and disease free survival
rate was 71.1% (See Additional file 1). Stage IV tumors
were associated with both decreased overall and disease-
free survival. Additionally, stage II tumors were associ-
ated with decreased disease-free survival.
Macrophage counts and Wilms tumor staging
We chose to immunostain for the CD68 macrophage
marker, the most widely used antigen in both clinical
and research settings. Additionally, its low cost and rela-
tive ease of staining compared to other markers makes
CD68 attractive as a candidate prognostic biomarker
for patient use. A relative limitation to the use of this
marker may be the need to confirm specificity [22].
However, in our study, cells that positively stained for
CD68 were subsequently confirmed to exhibit classic
histological characteristics of macrophages by two inde-
pendent pathologists. Tissue microarrays obtained from
the CHTN were used to allow for rapid processing and
analysis of 124 Wilms tumor cases.
ANOVA demonstrated a significant difference in mac-
rophage count densities when stratified by tumor staging
(p=0.029). Post hoc T-test analysis using Tukey’s method
showed a significant difference in mean macrophage
count density between stage IV and I, and stage IV and
III tumors (Figure 2). There was no significant difference
in mean count densities between stage IV and II tumors.
Mean count densities in stage II, III, and IV tumors were
significantly greater than the mean count density mea-
sured in normal kidney tissue as control.
Macrophage presence and disease free/overall survival
Cases with a mean macrophage count density 10 or less
were considered as having a low macrophage presence,
and those with mean count densities greater than 10
having a high macrophage presence. We selected thiscutoff for macrophage presence as a reasonable number
for general pathologic use. Overall survival and disease-
free survival did not significantly differ between low and
high macrophage presence groups (Figure 3). However,
in patients with stage II tumors, greater macrophage
presence was associated with decreased disease-free
survival (p=0.035, Figure 4). This observation was inde-
pendently corroborated with a Fisher’s Exact Test
demonstrating a significant association between greater
macrophage presence and disease relapse (p=0.01). Pa-
tients with stage IV tumors that have higher macrophage
presence also appear to have decreased disease free sur-
vival (Figure 4), but the study was inadequately powered
to detect a significant difference (p=0.575). Overall sur-
vival did not differ significantly between low and high
macrophage presence groups when tumor stages were
analyzed independently.
Macrophage count and microvascular invasion
25 Wilms Tumor cases obtained from the Columbia
University Medical Center Tumor Bank were stained for
macrophages and correlated with presence or absence of
microvascular invasion. Samples were considered having
high macrophage counts if the mean number of macro-
phages per high-powered field was greater than 50. In-
creased macrophage counts were significantly associated
with microvascular invasion (p=0.0004).
Discussion
In this report, we provide the first clinicopathologic
examination of macrophage presence in a pediatric solid
tumor. We used tissue microarrays to conduct our
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Figure 3 (A) Disease-free and (B) overall survival comparisons of patients with low and high macrophage count densities. Logrank
analysis was used to compare survival differences between the two populations.
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method of cohorting larger sample numbers and allo-
wing for more robust analysis of immunohistochemical
signal [16]. In prior studies, individual macrophages have
been manually counted or scored by blinded investiga-
tors [16,18,20,23], which can lead to inconsistent results.
To avoid this, we used an objective macrophage quanti-
tation method that provides for consistency and ease of
analysis. Our method employs digital image capturing
and processing to produce a macrophage “count density”
that can be easily interpreted and potentially utilized in
the clinical setting.
In our cohort of 124 Wilms tumor cases, we demon-
strated that the mean macrophage count density in stage
IV tumors was significantly higher than that of stage IStage I














































































Figure 4 (A) Disease-free survival and (B) overall survival comparison
stratified by Wilms Tumor staging. Logrank analysis was used to compaand III tumors. This finding indicates that increased
macrophage presence correlates with tumor stage, the
primary clinical factor directing choice of therapy. Intri-
guingly, sub-group analysis by tumor stage demonstrated
the macrophage density was significantly different when
disease-free survival in stage II patients was studied, al-
though overall survival did not differ between high and
low macrophage presence groups. Using an independent
set of samples from 25 patients, we also showed that in-
creased macrophage count is associated with the pres-
ence of tumor microvascular invasion, supporting future
investigation into the mechanism by which macrophage
recruitment promotes progression in Wilms tumor.
Tumor-associated macrophages have been shown ex-
perimentally to promote disease progression by suppor-Stage I
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s of patients with high and low macrophage count densities,
re survival between the two populations.
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studies also suggest that TAMs play a major role in acti-
vating the “angiogenic switch,” stimulating tumor angio-
genesis [10]. Our study is consistent with this concept,
and suggests an association between increased macro-
phage infiltration and the presence of microvascular
invasion by tumor cells. The mechanisms of disease pro-
motion by TAMs in pediatric solid tumors have not
been previously explored. Our study was limited by the
small amount of pre-selected tissue cores per case used
in immunohistochemistry, which could have underrepre-
sented the true number of macrophages in the tumor, as
well as the limited number of cases that is typical for
children’s cancers. However, our findings achieved statis-
tical significance despite these constraints, suggesting
that this may be a useful approach in the setting of chil-
dren’s cancers. Finally, although our study will need pro-
spective validation, we show that a relatively simple
technique might be an additional tool for prognosticat-
ing Wilms tumor cases during pathological review. Our
study was conducted with the approval and support of
the Renal Tumors Biology subcommittee of the Chil-
dren’s Oncology Group, the body which can implement
systematic biomarker study for pediatric solid tumors.
In summary, our findings suggest that macrophage
presence may be a useful adjunct in refining staging
algorithms for patients with pathologic stage II Wilms
tumor. As noted previously, these patients may be at risk
for sampling error and undertreatment. Examination for
macrophage presence in tumor samples could be used
to complement current pathologic assessments to guide
staging. By refining prognostic stratification between
stage II and III tumors, the risk of adverse effects associ-
ated with under- or overtreatment may be reduced. A
similar trend in stage IV patients did not achieve statistical
significance due to the small number of cases, and may
also be worthy of further examination. Increased macro-
phage presence was significantly associated with tumor
microvascular invasion, consistent with prior reports of
TAM function in other tumor systems. Taken together,
these data support further study of the role of macro-
phages in the pathobiology of pediatric Wilms tumor.Additional file
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